Ausgabe 1/2019
Inhalt (12 Artikel)
Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Sarah Sammons, Noah S. Kornblum, Kimberly L. Blackwell
Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Sarah Sammons, Noah S. Kornblum, Kimberly L. Blackwell
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Albert Font, Raquel Luque, José Carlos Villa, Montse Domenech, Sergio Vázquez, Enrique Gallardo, Juan Antonio Virizuela, Carmen Beato, Rafael Morales-Barrera, Antoni Gelabert, Sonia Maciá, Javier Puente, Gustavo Rubio, Xavier Maldonado, Begoña Perez-Valderrama, Alvaro Pinto, Ovidio Fernández Calvo, Enrique Grande, Javier Garde-Noguera, Eva Fernández-Parra, José Ángel Arranz
Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
Ilya Tsimafeyeu, Pavel Borisov, Ahmed Abdelgafur, Roman Leonenkov, Olga Novikova, Irina Guseva, Marina Demchenkova, Nadezhda Mikhailova, Andrey Semenov, Zakhar Yurmazov, Irina Sivunova, Madina Ramazanova, Sergey Gamayunov, Dmitry Kosov, Gennady Bratslavsky
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Maja J. A. de Jonge, Neeltje Steeghs, Martijn P. Lolkema, Sebastien J. Hotte, Hal W. Hirte, Diane A. J. van der Biessen, Albiruni R. Abdul Razak, Filip Y. F. L. De Vos, Remy B. Verheijen, David Schnell, Linda C. Pronk, Monique Jansen, Lillian L. Siu
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi, James Chih-Hsin Yang, Kohei Shitara, Yoichi Naito, Ann-Lii Cheng, Akiko Sarashina, Linda C. Pronk, Yoshito Takeuchi, Chia-Chi Lin
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520
Remy B. Verheijen, Diane A. J. van der Biessen, Sebastien J. Hotte, Lillian L. Siu, Anna Spreafico, Maja J. A. de Jonge, Linda C. Pronk, Filip Y. F. L. De Vos, David Schnell, Hal W. Hirte, Neeltje Steeghs, Martijn P. Lolkema
Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib
Maximilian J. Hochmair, Anna Buder, Sophia Schwab, Otto C. Burghuber, Helmut Prosch, Wolfgang Hilbe, Agnieszka Cseh, Richard Fritz, Martin Filipits
Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry
Li Chia Chong, Amanda Rose Townsend, Joanne Young, Amitesh Roy, Cynthia Piantadosi, Jennifer E. Hardingham, David Roder, Christos Karapetis, Robert Padbury, Guy Maddern, James Moore, Timothy Jay Price
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy
Zhuanglin Li, Mingxue Wang, Xuejing Yao, Wenting Luo, Yaocheng Qu, Deling Yu, Xue Li, Jianmin Fang, Changjiang Huang